For Dominik Heldt, the first sign that something was fundamentally different about his biology arrived at age 12. It began with a blurring of the world—a sudden, frightening loss of vision in one eye. Though physicians at the time suspected von Hippel-Lindau (VHL) disease, the lead was not pursued, leaving Dominik to navigate a childhood marked by medical ambiguity and the leisurely accumulation of uncertainty.
VHL is a rare genetic condition that predisposes individuals to develop tumors—both benign and malignant—across various organs. Globally, it affects approximately one in 36,000 people, leaving an estimated 100,000 to 150,000 patients worldwide to manage a lifelong precarious balance between surveillance and surgery. For Dominik, the diagnosis eventually became a roadmap for a life defined by resilience and a series of invasive interventions.
The trajectory of VHL is often a relentless cycle of “watch and wait.” Over the years, Dominik has undergone numerous operations to address tumors affecting his pancreas, epididymis, brain, and spine. While he expresses gratitude for avoiding dialysis and living without chronic pain, the physical toll is only half the story. For those living with VHL, the true burden is often psychological—the “scanxiety” that accompanies every routine check-up and the looming question of where the next tumor will appear.
The Shift from Surgery to Targeted Therapy
For decades, the primary weapon against VHL was the scalpel. Surgeons would remove tumors once they reached a certain size, but this approach was reactive, often requiring repeated surgeries that increased the risk of complications and permanent organ damage. However, 2024 marked a pivotal turning point for Dominik and many others in Switzerland.
Dominik became one of the first patients in the country to be treated with Belzutifan, a targeted therapy designed specifically for the molecular drivers of VHL. Unlike traditional chemotherapy, which attacks rapidly dividing cells indiscriminately, Belzutifan targets the hypoxia-inducible factor (HIF-2$alpha$). In patients with VHL, the loss of the VHL protein leads to an accumulation of HIF-2$alpha$, which in turn triggers the growth of tumors in the kidneys, pancreas, and central nervous system.
The impact on Dominik’s quality of life has been immediate. By slowing tumor growth and, in some cases, shrinking existing masses, the medication has shifted his perspective from crisis management to stability. “The medication gives me security,” Dominik explains. “I must think less about possible disease progressions.”
| Management Approach | Primary Goal | Patient Experience |
|---|---|---|
| Surgical Intervention | Tumor Removal | Recurring surgeries, recovery periods, risk of scarring. |
| Surveillance (Imaging) | Early Detection | High psychological stress; “waiting for the other shoe to drop.” |
| Targeted Therapy (Belzutifan) | Growth Inhibition | Stabilization of tumors, reduced surgical frequency, increased mental security. |
The Necessity of Interprofessional Coordination
Because VHL is a systemic disease, it cannot be managed by a single specialist. A patient might simultaneously require the expertise of a neurosurgeon for a brain lesion, a urologist for renal cysts, and an endocrinologist for pancreatic issues. This fragmentation of care can be overwhelming for patients, who often find themselves acting as their own medical coordinators, carrying files from one clinic to another.
For the past six years, Dominik has been under the care of PD Dr. Med. Christian Rothermundt, Co-Chief Physician of Medical Oncology at the LUKS Group (Luzerner Kantonsspital). The model employed at LUKS emphasizes a centralized point of contact supported by a highly networked interprofessional team. This structure ensures that the various specialists are not working in silos but are instead coordinating their strategies around the patient’s specific needs.
This “invisible” organization is, for Dominik, the most vital part of his care. “I don’t notice how everything is organized,” he says, “but I know that the specialist departments are working together.” This coordinated approach reduces the risk of contradictory treatments and ensures that the timing of screenings and interventions is optimized to preserve organ function.
Navigating the Rare Disease Landscape
The experience of VHL patients highlights a broader challenge in modern medicine: the “orphan” nature of rare diseases. When a condition affects only a small fraction of the population, patients often struggle to find physicians who are truly familiar with the nuances of their diagnosis. This isolation can exacerbate the psychological burden, making the role of specialized centers like LUKS even more critical.
The integration of new pharmaceuticals like Belzutifan into the standard of care represents a broader shift toward precision medicine. By targeting the genetic root of the problem rather than just the symptomatic growth, medicine is moving closer to a chronic-management model for VHL, rather than a series of emergency interventions.
Despite these advances, the journey remains demanding. The necessity of lifelong monitoring persists, as the genetic predisposition does not disappear. The goal, however, has shifted from merely surviving the next surgery to maintaining a high quality of life and mental well-being.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a qualified healthcare provider for diagnosis and treatment options.
As clinical data continues to accumulate on the long-term efficacy of HIF-2$alpha$ inhibitors, the next milestone for the VHL community will be the refinement of treatment protocols to determine the optimal timing for starting targeted therapy to maximize organ preservation. Continued monitoring of patients in the Swiss cohort will provide critical insights into the drug’s long-term safety and effectiveness.
Do you or a loved one navigate the challenges of a rare disease? Share your experiences or questions in the comments below, and share this story to help raise awareness for VHL.
Keep reading
